{"id":"riv","rwe":[],"_tga":{"status":"Registered","regulator":"TGA","artgNumber":""},"tags":[],"safety":{"safetySignals":[{"date":"","signal":"DISCOMFORT","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"INTENTIONAL SELF-INJURY","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"OVERDOSE","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"PRODUCT COLOUR ISSUE","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"SOPOR","source":"FDA FAERS","actionTaken":"Reported 1 times"}],"drugInteractions":[{"drug":"Atorvastatin","action":"Avoid","effect":"Increased risk of myopathy"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Digoxin","action":"Monitor","effect":"Increased risk of digoxin toxicity"},{"drug":"Ergot alkaloids","action":"Avoid","effect":"Increased risk of ergotism"},{"drug":"Fentanyl","action":"Monitor","effect":"Increased risk of respiratory depression"},{"drug":"Ketoconazole","action":"Avoid","effect":"Increased risk of ketoconazole toxicity"},{"drug":"Midazolam","action":"Monitor","effect":"Increased risk of midazolam toxicity"},{"drug":"Omeprazole","action":"Monitor","effect":"Increased risk of omeprazole toxicity"},{"drug":"Pimozide","action":"Avoid","effect":"Increased risk of pimozide toxicity"},{"drug":"Quinidine","action":"Avoid","effect":"Increased risk of quinidine toxicity"},{"drug":"Rifampicin","action":"Monitor","effect":"Decreased efficacy of rivastigmine"},{"drug":"Theophylline","action":"Monitor","effect":"Increased risk of theophylline toxicity"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of warfarin toxicity"}],"commonSideEffects":[{"effect":"Injection site pain (PAIN AT THE INJECTION SITE) left deltoid","drugRate":"56.2%","placeboRate":"","totalAtRisk":160,"totalAffected":90,"trialsReporting":1},{"effect":"Fatigue (FATIGUE)","drugRate":"36.2%","placeboRate":"","totalAtRisk":160,"totalAffected":58,"trialsReporting":1},{"effect":"Headache (HEADACHE)","drugRate":"24.4%","placeboRate":"","totalAtRisk":160,"totalAffected":39,"trialsReporting":1},{"effect":"Myalgia (NEW OR WORSENED MUSCLE PAIN)","drugRate":"13.1%","placeboRate":"","totalAtRisk":160,"totalAffected":21,"trialsReporting":1},{"effect":"Injection site pain (PAIN AT THE INJECTION SITE) right deltoid","drugRate":"11.9%","placeboRate":"","totalAtRisk":160,"totalAffected":19,"trialsReporting":1},{"effect":"Injection Site Pain","drugRate":"8.4%","placeboRate":"","totalAtRisk":190,"totalAffected":16,"trialsReporting":1},{"effect":"Injection Site Tenderness","drugRate":"8.4%","placeboRate":"","totalAtRisk":190,"totalAffected":16,"trialsReporting":1},{"effect":"Injection site swelling (SWELLING) left deltoid","drugRate":"9.4%","placeboRate":"","totalAtRisk":160,"totalAffected":15,"trialsReporting":1},{"effect":"Chills (CHILLS)","drugRate":"8.8%","placeboRate":"","totalAtRisk":160,"totalAffected":14,"trialsReporting":1},{"effect":"Injection site erythema (REDNESS) left deltoid","drugRate":"8.8%","placeboRate":"","totalAtRisk":160,"totalAffected":14,"trialsReporting":1},{"effect":"Diarrhoea (DIARRHEA)","drugRate":"8.1%","placeboRate":"","totalAtRisk":160,"totalAffected":13,"trialsReporting":1},{"effect":"Arthralgia (NEW OR WORSENED JOINT PAIN)","drugRate":"7.5%","placeboRate":"","totalAtRisk":160,"totalAffected":12,"trialsReporting":1},{"effect":"Headache","drugRate":"3.1%","placeboRate":"","totalAtRisk":350,"totalAffected":11,"trialsReporting":2},{"effect":"Malaise (Fatigue)","drugRate":"5.8%","placeboRate":"","totalAtRisk":190,"totalAffected":11,"trialsReporting":1},{"effect":"Nausea","drugRate":"2.0%","placeboRate":"","totalAtRisk":350,"totalAffected":7,"trialsReporting":2},{"effect":"Pyrexia (FEVER)","drugRate":"1.9%","placeboRate":"","totalAtRisk":160,"totalAffected":3,"trialsReporting":1},{"effect":"Injection site erythema (REDNESS) right deltoid","drugRate":"1.2%","placeboRate":"","totalAtRisk":160,"totalAffected":2,"trialsReporting":1},{"effect":"Injection site swelling (SWELLING) right deltoid","drugRate":"1.2%","placeboRate":"","totalAtRisk":160,"totalAffected":2,"trialsReporting":1},{"effect":"Vessel puncture site haemorrhage","drugRate":"0.6%","placeboRate":"","totalAtRisk":160,"totalAffected":1,"trialsReporting":1},{"effect":"Inguinal hernia","drugRate":"0.6%","placeboRate":"","totalAtRisk":160,"totalAffected":1,"trialsReporting":1},{"effect":"Norovirus infection","drugRate":"0.6%","placeboRate":"","totalAtRisk":160,"totalAffected":1,"trialsReporting":1},{"effect":"Road traffic accident","drugRate":"0.6%","placeboRate":"","totalAtRisk":160,"totalAffected":1,"trialsReporting":1},{"effect":"Hypercholesterolaemia","drugRate":"0.6%","placeboRate":"","totalAtRisk":160,"totalAffected":1,"trialsReporting":1},{"effect":"Type 2 diabetes mellitus","drugRate":"0.6%","placeboRate":"","totalAtRisk":160,"totalAffected":1,"trialsReporting":1},{"effect":"Vitamin D deficiency","drugRate":"0.6%","placeboRate":"","totalAtRisk":160,"totalAffected":1,"trialsReporting":1},{"effect":"Costochondritis","drugRate":"0.6%","placeboRate":"","totalAtRisk":160,"totalAffected":1,"trialsReporting":1},{"effect":"Musculoskeletal chest pain","drugRate":"0.6%","placeboRate":"","totalAtRisk":160,"totalAffected":1,"trialsReporting":1},{"effect":"Oropharyngeal pain","drugRate":"0.6%","placeboRate":"","totalAtRisk":160,"totalAffected":1,"trialsReporting":1},{"effect":"Lymphadenopathy","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Tinnitus","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Thyroid mass","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Fatigue","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Seasonal allergy","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"COVID-19","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Herpes zoster","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Pharyngitis streptococcal","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Sinusitis","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Viral upper respiratory tract infection","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Fall","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Muscle strain","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Myalgia","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Tendonitis","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Dizziness","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Restless legs syndrome","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1},{"effect":"Syncope","drugRate":"0.0%","placeboRate":"","totalAtRisk":160,"totalAffected":0,"trialsReporting":1}],"contraindications":["have liver disease associated with an increased risk of bleeding","have a body lesion at risk of bleeding, including active or recent bleeding in the brain, or bleeding in your stomach or gut","are taking other anticoagulants (blood thinners, e.g., warfarin, heparin, low molecular weight heparin, apixaban, dabigatran, edoxaban)","are taking certain medications such as cobicistat, ketoconazole, itraconazole, posaconazole, or ritonavir","are pregnant or breast-feeding","are bleeding actively or have a high risk of bleeds","are allergic to rivaroxaban or any ingredients of the medication","Heart valve disease: Rivaroxaban is not recommended for people who have artificial heart valves or have had artificial heart valves","Increased bleeding risk: If you have conditions that are associated with an increased risk of bleeding (e.g., bleeding problems; uncontrolled very high blood pressure; a problem with the blood vessels in the back of the eye called retinopathy; current or past ulcer of the stomach or intestine; or a history of stomach ulcers)"],"specialPopulations":{"Pregnancy":"Available data from reports of pregnancy in clinical trials with RIVFLOZA™ are insufficient to evaluate for unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In cases where RIVFLOZA™ is used in a pregnant woman, consider the potential risks to the fetus and the mother’s clinical need for RIVFLOZA™ and any potential adverse effects on the breastfed infant from RIVFLOZA™ or from the underlying maternal condition.","Geriatric use":"Clinical studies of RIVFLOZA™ did not include patients aged 65 and over to determine whether they respond differently from younger patients. No dose adjustment is recommended in patients ≥65 years old [see Clinical Pharmacology (12.3)].","Pediatric use":"The safety and effectiveness of RIVFLOZA™ have been established in pediatric patients aged 9 years and older. Use of RIVFLOZA™ in these age groups is supported by evidence from an adequate and well-controlled study.","Renal impairment":"No dose adjustment is recommended in patients with an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73 m2. RIVFLOZA™ has not been studied in PH1 patients with severe renal impairment (eGFR <30 mL/min/1.73 m2).","Hepatic impairment":"No dose adjustment of RIVFLOZA™ is recommended for patients with mild hepatic impairment (total bilirubin ≤ upper limit of normal [ULN] and aspartate aminotransferase [AST] > ULN or total bilirubin >1 to 1.5 times ULN and any AST.) RIVFLOZA™ has not been studied in patients with moderate or severe hepatic impairment (total bilirubin >1.5 ULN with any AST)."}},"trials":[],"_whoEML":{"listed":true,"source":"WHO EML"},"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_fixedAt":"2026-03-30T11:25:38.211338","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=riv","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:28:21.642752+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:28:27.553627+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:28:21.710271+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=riv","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:28:27.934147+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2104024/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:28:28.636669+00:00"}},"offLabel":[],"timeline":[],"_cochrane":[{"title":"To learn more, view the following link: Privacy Policy\nSkip to Content\n\nTrusted evidence.","source":"Cochrane Library"}],"_dailymed":{"setId":"e8e4275c-6cbe-4976-8cae-f62baf954d27","title":"RIVAROXABAN TABLET, FILM COATED [NOVADOZ PHARMACEUTICALS LLC]","labeler":""},"aiSummary":"RIV, developed by Pfizer Inc., is a marketed drug for HIV-1 infection treatment. It is used in combination with other antiretroviral agents in pediatric patients. The drug has generated significant revenue of 63.6B. RIV has undergone 12 trials and has been published in 371 studies. Its clinical differentiation and commercial significance are notable in the pharma industry. However, pipeline developments for similar treatments may impact its market share.","brandName":"Riv","ecosystem":[],"isGeneric":true,"mechanism":{"target":"HIV-1 protease","novelty":"best-in-class","modality":"small molecule","drugClass":"Protease Inhibitors","explanation":"","oneSentence":"","technicalDetail":"RIV's mechanism of action is based on its ability to inhibit the HIV-1 protease enzyme, which is essential for the virus's replication. This inhibition prevents the virus from maturing and being released from infected cells. As a result, the drug reduces the viral load and slows down the progression of the disease."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"USD 6000","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"Generic — multiple manufacturers","peakSalesEstimate":"$495,000"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=riv","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=riv","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:32:31.725652+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Repatha (evolocumab)","company":"Amgen","advantage":"PCSK9 inhibitor that reduces major adverse cardiovascular events"},{"name":"Rybelsus (semaglutide)","company":"Novo Nordisk","advantage":"Treats type 2 diabetes in adults 18+ and reduces cardiovascular risks"},{"name":"Simvastatin","company":"Merck & Co.","advantage":"Cardiovascular Risk Reduction"},{"name":"Vostally","company":"Unknown","advantage":"Unknown"},{"name":"Ozempic","company":"Novo Nordisk","advantage":"Treats type 2 diabetes in adults 18+ and reduces cardiovascular risks"},{"name":"Jardiance","company":"Boehringer Ingelheim","advantage":"Treats type 2 diabetes in adults 18+ and reduces cardiovascular risks"},{"name":"Wegovy","company":"Novo Nordisk","advantage":"Treats type 2 diabetes in adults 18+ and reduces cardiovascular risks"}],"genericName":"riv","indications":{"approved":[{"name":"HIV-1 infection","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","regulator":"FDA"},{"name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_drugWebsite":{"url":"https://riv.com","content":"Excellent\nTrustpilot\nAtom/ Ultra Premium Domains/ Riv.com\nRiv.com\nThe domain name, Riv.com is one of the most valuable brand assets on the market today. Secure Riv.com if you’re serious about building an incredible brand. Don’t wait. Once this name sells, it will be off the market forever.\nHear how Riv.com sounds Hear how it sounds  Check Brand Alignment\nAdd to Shortlist Add to Shortlist 148\nBuy Now\n$495,000\nPay in Installments \n$14,850\nx 36 months\nBuy With \nProceed to Payment\nSimple Buying Process\nClear and upfront pricing so that you can purchase the domains with confidence\nSecurely Submit\nYour Payment\nWe initiate most domain transfers within same business day of the purchase\nRapid Domain\nTransfer Process\n100% Purchase Protection Guarantee. Receive full refund if we are unable to transfer the domain for any reason\nGuaranteed\nDomain Delivery\nAbout Riv.com\n\nRiv.com, a remarkable one-word domain, exudes power and simplicity with its short, three-letter, one-syllable construct. Like a swift river flowing through the digital landscape, this domain name evokes a sense of dynamic motion and energy. It encompasses a multitude of meanings, from the literal representation of a waterway to metaphorical interpretations such as progress, connectivity, and innovation. Riv.com is a versatile choice for startups across diverse industries, including technology, finance, and design. Its brevity and memorability make it an invaluable asset, capturing attention effortlessly and positioning brands as leaders in their respective fields. With Riv.com, businesses can effortlessly ride the current of success.\n\nUltra Premium Domain Purchase Facts\nInvesting in a domain is like investing in prime online real estate. Most Ultra-premium domains increase in value over time.\nUltra-premium domains establish instant credibility and trust with customers and in your industry. \nUltra-premium domains are short, easy to say and spell, and memorable, making them ideal for building iconic brands and webs"},"_fixedFields":["generics(10)","patents(0)"],"_mhraChecked":true,"labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT06237049","phase":"PHASE2","title":"A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-01-31","conditions":"Influenza, Human, SARS-CoV-2 Infection, COVID-19","enrollment":644},{"nctId":"NCT04451954","phase":"PHASE1","title":"Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-07-02","conditions":"Influenza Immunisation, Healthy Volunteers","enrollment":210},{"nctId":"NCT04144179","phase":"PHASE1","title":"Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-06","conditions":"Influenza","enrollment":150},{"nctId":"NCT06518577","phase":"PHASE4","title":"Immunogenicity of Influenza Vaccinations","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-09","conditions":"Influenza","enrollment":605},{"nctId":"NCT06043193","phase":"","title":"Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-02-20","conditions":"Metastatic Neuroendocrine Tumour","enrollment":100},{"nctId":"NCT06695130","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-18","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT05514002","phase":"PHASE4","title":"Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years","status":"TERMINATED","sponsor":"Fatimah Dawood","startDate":"2022-09-13","conditions":"Influenza, Human","enrollment":3988},{"nctId":"NCT06136377","phase":"NA","title":"Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration.","status":"NOT_YET_RECRUITING","sponsor":"Centre Georges Francois Leclerc","startDate":"2024-01-31","conditions":"Patients With Metastatic Castration-resistant Prostate Cancer","enrollment":35},{"nctId":"NCT03969641","phase":"PHASE4","title":"Safety of RIV4 Versus IIV4 in Pregnant Women","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-09-05","conditions":"Safety, Adverse Event Following Immunisation, Birth Outcomes","enrollment":384},{"nctId":"NCT03573050","phase":"PHASE1","title":"Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","startDate":"2018-05-16","conditions":"Bioequivalence","enrollment":36},{"nctId":"NCT02600585","phase":"","title":"Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2015-11","conditions":"Human Influenza","enrollment":254648},{"nctId":"NCT00758381","phase":"PHASE2","title":"Metastatic Advanced Pancreas Sorafenib","status":"UNKNOWN","sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","startDate":"2007-08","conditions":"Locally Advanced Pancreatic Cancer","enrollment":114}],"_emaApprovals":[{"date":"","name":"RIV","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2104024","moleculeType":"Small molecule","molecularWeight":"382.49"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2104024","pubchemSID":"56373953"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":375,"therapeuticAreas":["Infectious Disease"],"_revenueScrapedAt":"2026-03-31 09:33:22.510114+00","biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 19","pmid":"41858049","title":"Recombinant vs Standard Influenza Vaccine in Adults With Severe Obesity: A Randomized Clinical Trial.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"date":"2026 Mar 4","pmid":"41829556","title":"Fault Detection and Monitoring in Induction Machines Using Data-Driven Model Drift Detection.","journal":"Sensors (Basel, Switzerland)"},{"date":"2026 May","pmid":"41794278","title":"Rivastigmine attenuates LPS-induced cardiotoxicity via modulation of ER stress, oxidative pathways and apoptosis: Evidence from a rat model.","journal":"Microvascular research"},{"date":"2026 Jan 22","pmid":"41601023","title":"Shifting Perspective in Influenza Vaccines Efficacy: How Risk Difference Shows an Alternative View of the Comparative Efficacy Profile of Newer and Enhanced Influenza Vaccines Compared to Standard, Egg-Based Vaccines.","journal":"Vaccines"},{"date":"2026 Feb 15","pmid":"41571077","title":"Cognitive enhancing effect of Canagliflozin in aluminum-induced rat model of Alzheimer's-like disease: Cross-talk between Amyloid-Β and BDNF/GSK-3β signaling.","journal":"European journal of pharmacology"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"_investorTranscripts":{"url":"https://www.pfizer.com/investors/events-and-presentations","source":"Investor transcripts","mentions":["Privacy Statement"]},"companionDiagnostics":[],"genericManufacturers":10,"_genericFilersChecked":true,"genericManufacturerList":["Alembic Pharms Ltd","Apotex Inc","Aurobindo Pharma","Cadila Pharms Ltd","Chartwell Rx","Dr Reddys Labs Inc","Macleods Pharms Ltd","Orbion Pharms","Sun Pharm","Watson Labs"],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Vaccine","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":6,"withResults":2},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:32:31.725652+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}